Core Viewpoint - Nutex Health Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between August 8, 2024, and August 14, 2025, impacting investors adversely [1][2]. Group 1: Allegations and Company Impact - The lawsuit claims that Nutex Health Inc. made false statements regarding its third-party vendor HaloMD, which allegedly engaged in fraudulent activities to achieve favorable arbitration results [1]. - It is alleged that revenues from Nutex's engagement with HaloMD were unsustainable due to the fraudulent nature of the conduct [1]. - The company purportedly overstated its ability to remediate material weaknesses in its internal controls over financial reporting, leading to improper accounting of stock-based compensation obligations [1]. - As a result of these issues, Nutex Health Inc. may have overstated its business and financial prospects, making public statements materially false and misleading [1]. Group 2: Legal Proceedings and Participation - Investors who suffered losses during the specified timeframe have until October 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [2]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [2].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Nutex Health Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on October 21, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Nutex securities between August 8, 2024, and August 14, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. Group 2: Case Allegations - The lawsuit alleges that Nutex made false and misleading statements regarding its financial practices and internal controls, particularly concerning its relationship with HaloMD, a third-party vendor [4]. - Specific claims include that Nutex engaged in fraudulent activities to inflate revenues and overstated its ability to remediate internal control weaknesses [4]. - The lawsuit asserts that these misrepresentations led to an inability to accurately account for stock-based compensation obligations, increasing the risk of delayed financial reporting to the SEC [4].